BioSpace News Archive

Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q), the Company developing new classes of synthetic anti-infectives, today announced it has received Human Research Ethics Committee (HREC) approval to start its Phase I intravenous (IV) clinical trial evaluating the safety and pharmacokinetics of its lead compound, RECCE® 327 (R327).

BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) today announced that the FDA has authorized the company to initiate a Phase 2 study assessing NE3107’s potential pro-motoric impact in Parkinson’s disease patients.

A new health economic model developed by Aquarius Population Health and recently published in Preventive Medicine Reports shows that if an mRNA human papillomavirus (HPV) test were implemented in Ontario as part of a cervical cancer screening program in place of a DNA test, it could save the province over $4 million annually and avoid unnecessary colposcopies and additional screening tests.

Akebia Therapeutics, Inc. today announced plans to release its financial results for the third quarter ended September 30, 2021, on Thursday, November 4, 2021 before the opening of the financial markets.

Currax Pharmaceuticals, LLC today announced the appointment of Ed Cinca to the role of Senior Vice President (SVP)

The National Kidney Foundation Board of Directors selected former National Security Council official, New York energy and investment executive, and living-donor Tracy McKibben as the next Chair-Elect at their recent quarterly meeting.

Establishment Labs Holdings Inc. plans to announce its financial results for the quarter ended September 30, 2021, before the market opens on Tuesday, November 9, 2021, and will host a conference call at 8:30 am ET that day to discuss those results.

OpRegen ® Data Update to Be Featured at 2021 American Academy of Ophthalmology Annual Meeting in Presentation by Michael S. Ip, M.D.

BrickBio, the leader in site specific bioconjugation has launched a collaboration SiteSelect™ Panel for pharmaceutical and drug development partners to streamline ADC site optimization for all linker and payload combinations, delivering another platform to identify higher performing biologics.

Covetrus® (NASDAQ: CVET), a global leader in animal-health technology and services, announced today that it will release third quarter 2021 results after the market closes on Thursday, November 4 , 2021.